Canada-headquartered medical device company Ventripoint Diagnostics Ltd. has announced a new distributor partnership with UK based CardioLogic Ltd.
The partnership will help to market Ventripoint’s products and to expand its footprint across the UK. The agreement will also deliver improved cardiac facilities for surgeons and patients in the UK, such as the VMS+3.0, which is designed to provide fast and reliable diagnostic imaging.
Ventripoint CEO Dr. George Adams commented: “After interviewing a number of potential distribution partners in the United Kingdom (UK), we are pleased to have come to an agreement with CardioLogic. CardioLogic’s position as a leader in the cardiology market in the UK and its extensive network provides an excellent opportunity for Ventripoint to reach new customers in the UK market quickly.”
CardioLogic’s customer base and experience within the UK market will help Ventripoint to gain approval for purchase or lease in UK hospitals.
Martyn Dixon, Managing Director of CardioLogic, said: “We are very excited to enter into this partnership with Ventripoint Diagnostics and integrate the VMS+ with our range of innovative products that we currently offer. In addition to being a great and unique complement for cardiac ultrasound, they have demonstrated an accuracy equivalent to cardiac MRI."
"We are eager to commence this partnership and look forward to leveraging the VMS+3.0 with our extensive network of client contacts to drive adoption and growth into the UK market.”
Ventripoint is continuing to interview for regional distributors in Europe and the United States and says that it hopes to announce more partnerships soon.